HEADLINES

-=6

Indian Market
Indian equity markets were down 0.08% Nifty up by 4.45 pts and settle at 5854.75 Sensex up by 14.68 pts at 19331.69 Bank Nifty down by 58.50 pts at 12042.00

DAILY EQUITY NEWSLETTER

26TH FEBRUARY 2013

Global Market

European markets were up with FTSE up by 32.00 closed at 6367 ,CAC up by 26.84 closed at 3733 and DAX up by 103.69 closed at 7765. Dow future was up 25.00 closed at 14006.00

HEADLINES
Coal India sure of NTPC signing FSA; warns of price hike SBI fixes issue price at Rs 2312 for preferential allotment Mid-cap, smallcap stocks crash; regulators begin probe Ranbaxy up on restart of Atorvastatin production in the US

WWW.EPICRESEARCH.CO

09752199966

 MARKET ANALYSIS:
Key benchmark indices eked out small gains in choppy trade on the first day of a crucial week. The barometer index, the S&P BSE Sensex, advanced 14.68 points or 0.08%, off about 80 points from the day's high and up close to 95 points from the day's low. Index heavyweight and cigarette major ITC settled flat after witnessing intraday volatility. Index heavyweight Reliance Industries (RIL) dropped. S&P BSE Sensex was up 14.68 points or 0.08% at 19,331.69, its highest closing level since 20 February 2013. CNX Nifty was up 4.45 points or 0.08% at 5,854.75, its highest closing level since 20 February 2013.. Among the 30-share Sensex pack, 15 stocks gained while the rest of them declined Cairn India rose 0.31%. The company said after market hours today, 25 February 2013, that following endorsement of the exploration Work Programme for the Rajasthan Block (RJ-ON-90/1) by the Management Committee less than two weeks ago, Cairn India has today, 25 February 2013, commenced drilling of the first exploration well, after a gap of more than four years, in the prolific Barmer Basin. Among other FMCG stocks, Tata Global Beverages, Dabur India, Godrej Consumer Products and Hindustan Unilever dropped by 0.89% to 3.76%.GlaxoSmithkline Consumer Healthcare was up 0.53%. The company announced during trading hours today, 25 February 2013, that Life Insurance Corporation of India has sold 16.71 lakh equity shares of the company at Rs 3,900 per share.

FIIs and DIIs

CATEGORY DATE BUY SELL NET

STOCKS TO WATCH ADANI ENTERPRISE AUROBINDO PHARMA AMBUJA ITC

FII DII

25-Feb-13 25-Feb-13

2527.79 820.75

2281.08 982.72

246.71 -161.97

NIFTY DAILY PIVOTS

PIVOT NIFTY R4 6011 R3 5958 R2 5905 R1 5879 PP 5852 S1 5826 S2 5799 S3 5746 S4

SCRIPS IN BAN PERIOD

IFCI PUNJLYOD SUZLON RENUKA WELCORP

5693

WWW.EPICRESEARCH.CO

09752199966

GAINERS AND LOOSERS

EXPERT OPINION
NIFTY

DAILY NIFTY GAINERS

SCRIPS RATE VOL. (000) PR. CLOSE NET CHAN GE % CHANG E

Nifty looks Consolidate Strategy: Sell on rise Support: 5800 Resistance: 5900
BANK NIFTY

Ranbaxy Labs. Power Grid Corpn. Infosys Tata Motors HCL Tech.

433.85 112.05 2917.80 299.15 733.55

1836.44 8990.45 1307.15 5915.78 856.83

413.55 109.05 2840.55 292.90 720.25

20.30 3.00 77.25 6.25 13.30

4.91 2.75

Bank Nifty looks Consolidate Strategy: Sell on rise Support: 11970 Resistance: 12110 460

2.72 2.13 1.85

.0 PREVIOUS PERFORMANCE
TYPE SCRIP B/S RESULT

DAILY NIFTY LOOSERS

SCRIPS RATE VOL. (000) PR. CLOSE NET CHAN GE % CHAN GE

CASH CASH FUTURE FUTURE

ANDHRA BANK BHARTI AIRTEL AUROBINDO PHARMA AMBUJA

S B S B

TARGET HIT TARGET HIT TARGET HIT TARGET HIT

DLF JP Associate Cipla Larsen & Toubro ONGC

271.65 68.00 370.40 1401.85 317.90

9267.08 23374.96 1479.98 1204.00 3292.71

281.45 70.25 380.70 1435.30 323.90

-9.80 -2.25 -10.30 -33.45 -6.00

-3.48 -3.20 -2.71 -2.33 -1.85

UPCOMING RESULTS
BATA INDIA RANBAXY

WWW.EPICRESEARCH.CO

09752199966

MARKET CALLS
CASH
SCRIPS AUROBINDO PHARMA JAIPRAKASH ASSOCIATE ACTION SELL SELL LEVEL 172.80 67.50 1ST TARGET 171.80 67.00 2ND TARGET 170.80 66.25 STOP LOSS 173.80 68.00

FUTURE
SCRIPS . ADANI SELL 222.00 221.00 219.50 223.00 ACTION LEVEL 1
ST

TARGET

ND

TARGET

STOP LOSS

AMBUJA

BUY

201.00

202.00

203.50

200.00

Disclaimer
The information and views in this report, our website & all the service we provide are believed to be reliable, but we do not accept any responsibility (or liability) for errors of fact or opinion. Users have the right to choose the product/s that suits them the most. Sincere efforts have been made to present the right investment perspective. The information contained herein is based on analysis and up on sources that we consider reliable. This material is for personal information and based upon it & takes no responsibility The information given herein should be treated as only factor, while making investment decision. The report does not provide individually tailor-made investment advice. Epic research recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. Epic research shall not be responsible for any transaction conducted based on the information given in this report, which is in violation of rules and regulations of NSE and BSE. The share price projections shown are not necessarily indicative of future price performance. The information herein, together with all estimates and forecasts, can change without notice. Analyst or any person related to epic research might be holding positions in the stocks recommended. It is understood that anyone who is browsing through the site has done so at his free will and does not read any views expressed as a recommendation for which either the site or its owners or anyone can be held responsible for . Any surfing and reading of the information is the acceptance of this disclaimer. All Rights Reserved. Investment in equity & bullion market has its own risks. We, however, do not vouch for the accuracy or the completeness thereof. we are not responsible for any loss incurred whatsoever for any financial profits or loss which may arise from the recommendations above epic research does not purport to be an invitation or an offer to buy or sell any financial instrument. Our Clients (Paid Or Unpaid), Any third party or anyone else have no rights to forward or share our calls or SMS or Report or Any Information Provided by us to/with anyone which is received directly or indirectly by them. If found so then Serious Legal Actions can be taken.